

NCT ID	NCT04008030
Title	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
Phase	Phase 3
Date Added	2019-07-05
Location	California, United States Colorado, United States Illinois, United States New York, United States Oregon, United States Pennsylvania, United States Texas, United States Virginia, United States Argentina Australia Austria Belgium Brazil Canada Chile China Czechia Denmark France Germany Greece Ireland Italy Japan Netherlands Norway Puerto Rico Romania Spain Turkey United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd
NCT ID	NCT04003792
Title	Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
Phase	Phase 2
Date Added	2019-07-01
Location	Israel
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Bevacizumab, FOLFIRI Protocol, oxaliplatin
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03994601
Title	An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Phase	Phase 1
Date Added	2019-06-21
Location	California, United States Colorado, United States Maryland, United States Missouri, United States New Jersey, United States Argentina Canada Chile France Italy Spain
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	BMS-986288, Nivolumab, Opdivo
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03990233
Title	A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
Phase	Phase 1
Date Added	2019-06-18
Location	Belgium France
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	BI 754091, BI 765063
Tags	MSS/ MMRp
NCT ID	NCT03985891
Title	The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Phase	Phase 1/Phase 2
Date Added	2019-06-14
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03984578
Title	Window of Opportunity Study in Colorectal Cancer
Phase	Phase 2
Date Added	2019-06-13
Location	Singapore
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Capecitabine/ 5-FU, CapeOX, Pembrolizumab, Eloxatin, Keytruda
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT03983993
Title	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2019-06-12
Location	Georgia, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Niraparib, panitumumab, Vectibix, Zejula
Tags	MSS/ MMRp
NCT ID	NCT03981146
Title	A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Phase	Phase 2
Date Added	2019-06-10
Location	United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nivolumab, Opdivo
Tags	MSS/ MMRp
NCT ID	NCT03977090
Title	Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2019-06-06
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Fruquintinib, Geptanolimab Injection, Elunate
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03970382
Title	A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Phase	Phase 1
Date Added	2019-05-31
Location	California, United States Illinois, United States New York, United States Tennessee, United States Washington, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Suspended
Drugs	IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab
Tags	MSS/ MMRp